Eltrombopag
Eltrombopag is a drug of the class of thrombopoetine receptor agonists. Since 2010, the substance has also been approved in the EU, before that it was only approved in the US. In 2015, the indication of idiopatic thrombocytopenic purpura (ITP) was extended to include severe aplastical anemia (SAA), in which other therapies do not strike. No serious side effects have been observed, however side effects are very common.
Description
Formula
Molecular weight
Molecular size
Controlled Substance
Precursor
Indications
Your Contact
Marius Hang
International Division
Director API Export
Rheinstr. 49
55218 Ingelheim
Germany
-
Disclaimer
The information contained herein is the proprietary information of Midas Pharma GmbH and its affiliates. This information is provided to you solely for your evaluation, to determine your interest in a potential business relationship with Midas Pharma GmbH and/or its affiliates. Midas Pharma GmbH excludes any express or implied representations, guarantees or warranties of whatsoever nature, including but not limited to the warranties for the completeness or accuracy of the information provided herein.
No information provided herein – including any reference to any product or service – constitutes an offer for sale, or shall be construed as representing an offer for sale. In particular, nothing herein should be construed as a promotion or advertisement for any product, or for the use of any product, that infringes valid patents and/or is not authorized by the laws and regulations of your country of residence.